Cisplatin Chemoradiation Remains Gold Standard for Low-Risk HPV+ SCCHN

The incidence of human papilloma virus (HPV)-positive squamous cell carcinoma of the head and neck (SCCHN) is increasing. Oropharyngeal squamous cell carcinoma is considered a distinctive disease from HPV-negative cancer and has a better prognosis. Currently, the treatment of oropharyngeal cancer without distant metastases is similar for both HPV-positive and HPV-negative disease, with concomitant cisplatin-based […]

Read More

First-Line Avelumab Plus Axitinib Outperforms Sunitinib in RCC

For many years, the standard front-line therapy for advanced renal cell carcinoma (RCC) with clear cell histology was single-agent treatment with a vascular endothelial growth factor (VEGF) targeting tyrosine kinase inhibitor (TKI). Recently, however; immunotherapy with the PD-1 inhibitor nivolumab in combination with the CTLA-4 inhibitor ipilimumab was approved for use in patients with intermediate- […]

Read More

Atezolizumab Combo, a New First-Line Option for Advanced NSCLC

For newly diagnosed patients with advanced non-small cell lung cancer (NSCLC) without targetable driver mutations, the standard of care for many years was platinum-doublet chemotherapy. Recently, however; immunotherapy with PD-1 inhibitor pembrolizumab, either alone (for patients with PD-L1 expression over 50%) or in combination with platinum-based chemotherapy were approved as new standard for first-line treatment […]

Read More

First-Line Pembrolizumab Superior to EXTREME in Metastatic SCCHN

For years, first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) has been the combination of platinum chemotherapy, 5-fluorouracil (5-FU), and cetuximab followed by cetuximab maintenance, commonly known as the EXTREME regimen. This regimen is associated with an overall survival (OS) of about 10 months. It has substantial toxicity but is […]

Read More

Local RT Improves Survival in Low Metastatic Burden Prostate Cancer

Men with newly diagnosed, metastatic prostate cancer are typically treated with systemic therapy, including androgen deprivation therapy (ADT), and receive local therapy for symptom palliation if needed. However, retrospective data suggest that local radiotherapy to the primary tumor may have an impact on survival in metastatic prostate cancer and patients with better prognoses may benefit […]

Read More

First-Line Olaparib Maintenance New Standard for BRCAm Ovarian Cancer

Treatment for newly diagnosed advanced ovarian cancer most often includes cytoreductive surgery and platinum-based chemotherapy. While this combination is highly effective, most patients will relapse within three years. For recurrent platinum-sensitive ovarian cancer, maintenance with poly(ADP-ribose) polymerase (PARP) inhibitors such as olaparib, niraparib, and rucaparib is standard of care following platinum-based chemotherapy, based on substantial […]

Read More

Survival Benefit of Palbociclib/Fulvestrant in HR+/HER2- Breast Cancer

In recent years and across multiple lines of therapy, the combination of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors with hormonal therapy has become a standard of care for patients with advanced, hormone-receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative breast cancer. As previously reported, in the PALOMA-3 trial (N = 521) the combination of the CDK4/6 […]

Read More

Atezolizumab/Nab-Paclitaxel Combo New Standard of Care for PD-L1+ TNBC

The 2018 European Society for Medical Oncology (ESMO) Congress was held from October 19 to 23 in Munich, Germany. Nearly 28,000 participants, including oncology professionals, patient advocates, and industry representatives, attended from around the world to hear the most recent updates in oncology, focusing on innovation, integration, and sustainability of cancer care. Over the next […]

Read More

liquid-biopsy-nsclc-primelines

Utility of Liquid Biopsy for Mutation Detection in NSCLC

In non-small lung cancer (NSCLC), genetic alterations in genes such as EGFR, ALK, ROS1, and BRAF have been validated as reliable targets, and molecular testing and genotype-driven targeted therapy is the standard of care for patients with advanced NSCLC harboring these alterations. However, tumor tissue may be difficult to obtain or yield inadequate samples to […]

Read More

Lurbinectedin Active in BRCA1/2-Mutated Advanced Breast Cancer

Patients with advanced breast cancer who carry germline mutations in BRCA1/2 genes are highly sensitive to DNA damage due to deficiencies in homologous recombination repair (HRR) mechanisms. Lurbinectedin, an analog of the DNA damaging agent trabectedin, is a selective inhibitor of the transcription of protein-coding genes that results in accumulation of double-strand DNA breaks. In […]

Read More